Lost password ?
Gulf Pharmaceutical
JULPHAR, ORGANIC OR EXTERNAL GROWTH?
Jun 20 - Julphar (Buy, UAE) is the fourth worst YTD performer among our 6-stock Pharma coverage (€761m market capitalisation), losing almost 6% since the beginning of the year. As already been mentioned, ...
Executive summary
Conflict of Interest
Pages 39
Language English
Publish on June 20, 2018
€ 500
VAT Exl.
You might be also interested by these reports :
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.